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According to the WHO, there is an urgent need for better control of viral diseases. Re-positioning 
existing safe-in-human antiviral agents from one viral disease to another could play a pivotal role in 
this process. Here, we reviewed all approved, investigational and experimental antiviral agents, which 
are safe in man, and identified 59 compounds that targe  at least three viral diseases. We tested 55 of
these compounds against eight different RNA and DNA viruses. We found novel activities for 
dalbavancin against echovirus 1, ezetimibe against human immunodeficiency virus 1 and Zika virus, 
as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against Rift valley fever 
virus. Thus, the spectrum of antiviral activities of existing antiviral agents could be expanded towards 
other viral diseases.  
1. Introduction 
Dozens of viruses, such as FLUAV, HSV-1, VZV, CMV and NoV, constantly infect human 
population and represent substantial public health nd economic burden (DALYs and Collaborators, 
2017; Disease et al., 2017). Emerging and re-emerging v ruses, such as EBOV, MARV, LASV,  
CHIKV, ZIKV, DENV, RVFV, MERS- and SARS-CoV, surface from natural reservoirs 
approximately one each year and also represent global threats (Howard and Fletcher, 2012; WHO, 
2015). According to WHO, there is an urgent need for better control of these viruses, including drug-
resistant and vaccine immunity escaping viral strains (Bekerman and Einav, 2015; De Clercq and Li, 
2016). 
Antiviral drugs and vaccines are the most powerful too s to combat viral diseases. Most drugs and 
vaccines, however, selectively target a single virus, thereby providing a “one drug-one bug” solution. 
By contrast, broad-spectrum antivirals (BSAs) can cover multiple viruses and genotypes and reduce 
the likelihood of development of resistance. Therefor , some BSAs can be used for rapid management 
of new or drug-resistant viral strains, for treatment of viral co-infections reducing therapy complexity, 
















and cost issues associated with the development of virus-specific drugs and vaccines, the development 
of BSAs should be prioritized (Bekerman and Einav, 2015). 
Nucleotide and nucleoside analogues are excellent examples of BSAs. They inhibit transcription 
and/or replication of different RNA and DNA viruses (De Clercq, 2015). In particular, valaciclovir 
inhibits replication of different herpesviruses and HBV (Laube et al., 2004; Vere Hodge and Field, 
2013). Cidofovir and its lipid conjugate brincidofovir also inhibit replication of dsDNA viruses, such 
as herpesviruses, AdV, BKV, and HPV (Andrei et al., 2015). Ribavirin blocks viral RNA synthesis of 
FLUAV, HCV and RSV (Hong and Cameron, 2002). Favipiravir and BCX4430 also inhibit replication 
of different RNA viruses (McKimm-Breschkin et al., 2018). However, viruses are able to develop 
resistance to some of these nucleotide and nucleosid  analogues. 
Other examples of BSA agents include inhibitors of cellular pathways, which are exploited by 
different viruses for efficient viral replication (Debing et al., 2015). These agents overcome the 
problem of antiviral drug resistance. For example, lipid-lowering statins (atorvastatin, lovastatin, 
simvastatin, and fluvastatin) inhibit cellular HMG-CoA reductase and attenuate replication of some 
enveloped viruses (Bernal et al., 2017; Enserink, 2005). Anti-malaria quinolones (chloroquine and 
hydroxychloroquine) inhibit acidification of endosomes, which is an essential process for uncoating of 
ssRNA viruses (Al-Bari, 2017). Anticancer kinase inhibitors dasatinib, imatinib, gefitinib, nilotinib, 
erlotinib and sunitinib impair intracellular viral trafficking and exert BSA effects (Bekerman et al.,
2017; Schor and Einav, 2018). The anti-Duchenne muscular dystrophy agent, alisporivir, targets 
cellular cyclophilin and inhibits the folding of HCV, HIV, MERS- and SARS-CoV proteins, and, 
therefore, prevents formation of infectious virus particles (Boldescu et al., 2017; de Wilde et al., 2017; 
Soriano et al., 2011). Thus, both host-directed antivirals and nucleotide/nucleoside analogues could 
possess BSA activity. 
Here, we hypothesised that some of the identified safe-in-human BSAs could possess novel 
















prove this hypothesis, we reviewed safe-in-man approved, investigational and experimental antiviral 
agents. We identified 59 compounds that target at le st three viral diseases. We tested 55 of the 59 
compounds against 8 different viruses and found novel antiviral activities for 7 of these agents. We 
conclude that the spectrum of antiviral activities for existing BSA agents could be expanded towards 
other viral diseases. 
2. Materials and methods 
2.1. Bioinformatics 
Information on the viruses and associated human diseases is summarized in Table S1. Information 
on approved, investigational and experimental safe-in-human antivirals is summarized in Tables S2-
S4. This information was extracted from DrugBank, clini al trials websites and PubMed (2018a; 
2018b; 2018c). Information on 59 approved, investigational, and experimental antivirals, which target 
≥3 viral diseases, is summarized in Table S5. Eye diagrams and interaction network plots were created 
with JavaScript library D3.js v4 (2018c). A structural similarity plot for the drugs was constructed and 
visualized using a C-SPADE web application (Ravikumar et al., 2017).  
2.2. Compounds 
The compounds used in this study, their suppliers and catalogue numbers are summarized in Table 
S6. To obtain 10 mM stock solutions compounds were dissolved in 100% dimethyl sulfoxide (DMSO, 
Sigma-Aldrich) or milli-Q water. The solutions were stored at −80 °C until use. 
2.3. Cells  
BHK-21 cells (baby hamster kidney fibroblasts) were grown in Glasgow’s Minimal Essential 
Medium (GMEM) containing 7.5% fetal bovine serum (FBS; Gibco, Paisley, UK), 2% tryptose 
phosphate broth (TPB), 200 mM HEPES, 100 U/ml penicilli  and 0.1 mg/ml streptomycin (PenStrep, 
Lonza Basel, Switzerland). ACH-2 cells, a model for chronic HIV-1 infection, which possesses a 
single integrated copy of the provirus HIV-1 strain LAI (NIH AIDS Reagent Program), were grown in 
















epithelial (MDCK) cells, human embryonic kidney cells (HEK293T) and African green monkey 
kidney epithelial cells (Vero) were grown in Dulbecco modified Eagle's medium (DMEM; Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 2 mM L-glutamine (Lonza; Basel, Switzerland), 50 
U/ml PenStrep and 10% FBS. Human telomerase reverse transcriptase-immortalized retinal pigment 
(RPE) cells were grown in DMEM-F12 medium supplemented with 50 U/ml PenStrep, 2 mM L-
glutamine, 10% FBS, and 0.25% sodium bicarbonate (Sigma-Aldrich). TZM-bl cells were grown in 
DMEM supplemented with 10% heat-inactivated FBS andPenStrep. Human lung adenocarcinoma 
epithelial cells, A549, were cultured in DMEM contai ing 0.75 g/L NaHCO3, 20 mM HEPES 
(EuroClone, Milan, Italy), PenStrep, and 5% fetal bovine serum (FBS, Gibco) at 37 °C. All cell lines 
were grown in humidified incubator at 37°C in the pr sence of 5% CO2. 
2.4. Viruses 
Human influenza A/WSN/33(H1N1) virus was generated using eight-plasmid reverse genetics 
system in HEK293 and Vero-E6 cells, as described prviously (Hoffmann et al., 2000). EV1 strain was 
propagated in a monolayer of Vero cells, as described earlier (Myllynen et al., 2016). HSV-1 was 
amplified in Vero cells, as described previously (Nygardas et al., 2013). ZIKV FB-GWUH-2016 strain 
was cultured in Vero E6 cells, as described earlier (Driggers et al., 2016).  
For production of HIV-1, 6×106 ACH-2 cells were seeded in 10 mL of full culture mdia, and HIV-
1 production was induced by the addition of 100 nM phorbol 12-myristate 13-acetate (Viira et al., 
2016). The induced cells were incubated for 48 h, and subsequently, the HIV-1 containing media was 
collected and filtered. The amount of HIV-1 in the stock was estimated by quantification of p24 
protein in the media. Quantity of p24 was measured sing a reference recombinant purified p24 protein 
and anti-p24-ELISA, which was developed in-house.  
CHIKV-2SG-NanoLuc strain was generated from icDNA clone of pICRES1 representing 
LR2006OPY1 strain belonging to East/Central/South African genotype (Utt et al., 2016). RRV-2SG-
















protein was placed between non-structural and structural regions of CHIKV or RRV genomes under 
the control of native subgenomic promoters of the viruses. To ensure expression of viral structural 
proteins, a copy of subgenomic promoter (residues -77 to +69 for CHIKV and residues -77 to +49 for 
RRV, positions given with respect to start site of subgenomic RNA) was inserted immediately 
downstream of sequence encoding for NanoLuc. 
Recombinant RVFV expressing the far-red fluorescent pro ein Katushka instead of the deleted NSs 
protein (rRVFV∆NSs::Katushka) was used in this study (Islam et al., 2018). 
The virus stocks were stored at -80 °C. All the experiments with viruses were performed in 
compliance with the guidelines of the national authori ies using appropriate Biosafety laboratories 
under appropriate ethical and safety approvals. 
2.5. Virus titration 
FLUAV virus was titrated in MDCK cells using plaque assay as described previously (Denisova et 
al., 2012). EV1 titers were determined by plaque assay on A549 cells, as described earlier (Marjomaki 
et al., 2002). ZIKV titers were determined by plaque assay on VERO-E6 cells, as described earlier 
(Kuivanen et al., 2017). HSV-1 titers were determined by plaque titration in Vero cells in the presence 
of human immunoglobulin G (20 µg/mL), as described earlier (Paavilainen et al., 2016). CHIKV-2SG-
NanoLuc and RRV-2SG-NanoLuc were titrated in BHK-21 cells using plaque assay, as described 
previously (Oo et al., 2018; Taylor et al., 2016). 
2.6.  Compound toxicity and efficacy assays 
For testing the viability and death of compound-treated mock-, FLUAV-, EV1-, CHIKV-2SG-
NanoLuc-, RRV-2SG-NanoLuc-, ZIKV- and HSV1-infected cells, approximately 4×104 RPE cells 
were seeded in each well of a 96-well plate. The cells were grown for 24 h in cell growth medium. The 
media was replaced with virus growth medium (VGM) containing 0.2% BSA, 2 mM L-glutamine, 
0.35% NaHCO3, and 1 µg/mL L-1-tosylamido-2-phenylethyl chloromethyl ketone-trypsin (TPCK)-
















F12 medium supplemented with 50 U/ml PenStrep, 2 mM L-glutamine, 2% FBS, and 0.25% sodium 
bicarbonate. The compounds were added to the cells in three-fold dilutions at seven different 
concentrations starting from 30 µM. No compounds were added to the control wells. The cells were 
mock- or virus- infected at a multiplicity of infection (MOI) of one. When virus induced a cytopathic 
effect in cells (typically 24 - 72 hpi), CellTox Green Express cytotoxicity reagent (CTxG, 1:2000 
dilution in the assay well, Promega, Madison, WI, USA) was added in VGM and the fluorescence was 
measured with a PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany) or Hidex sense 
microplate reader (Hidex Oy, Turku, Finland). The mdia was removed from the cells and stored at -
80°C. CellTiter-Glo viability reagent (CTG, Promega, Madison, WI, USA) containing firefly 
luciferase and luciferin was added (30 µL per well). The luminescence was measured with a 
PHERAstar FS plate reader.  
For testing virus titers in compound-treated and non-treated FLUAV-, EV1-, ZIKV- and HSV1-
infected cells the media was collected, serially diuted in PBS, and added to MDCK (FLUAV), A549 
(EV1), and Vero-E6 (ZIKV and HSV-1) cells. The media was changed, and the cells were overlaid 
with plaque assay media. The cells were fixed, and viral titers were calculated. The titers were 
expressed as plaque-forming units per ml (PFU/ml).  
The presence of CHIKV-2SG-NanoLuc and RRV-2SG-NanoLuc in the media from non- or drug-
treated RPE cells was evaluated by passaging the viruses in fresh RPE cells. The viruses expressed 
nano-luciferase from viral promoter, which was measured from lysed cells 8 h post infection using 
Renilla luciferase assay (Promega, Madison, WI, USA).   
For testing compound toxicity and efficacy against HIV-1, approximately 4×104 TZM-bl cells were 
seeded in each well of a 96-well plate. TZM-bl cells express firefly luciferase under control of HIV-1 
LTR promoter allowing quantitation of the viral infection (tat-protein expression by integrated HIV-1 
provirus) using firefly luciferase assay. The cells were grown for 24 h in cell growth medium. 
















from 30 µM. No compounds were added to the control wells. The cells were infected with HIV-1 
(media that contained 30 ng of HIV-1 p24 was used pr well) or mock. At 48 hpi, CellTox Green 
Express cytotoxicity reagent (CTxG, 1:2000 dilution n the assay well) was added and the fluorescence 
was measured with a PHERAstar FS plate reader. The media was removed from the cells, the cells 
were lysed, and firefly luciferase activity was measured using the Luciferase Assay System (Promega, 
Madison, WI, USA) and PHERAstar FS plate reader. 
To determine the efficacy of compounds against RVFV, the fluorescent intensity of individual 
infectious cell foci was quantified. Briefly, A549 cells (1×104 /well) were grown in 96-well black 
plates with transparent bottoms (Greiner Bio-One Int rnational). Compounds were serially diluted in 
DMSO in two-fold steps from 100 µM to 0.39 µM and mixed with 3000 pfu of 
rRVFV∆NSs::Katushka virus in a total volume of 100 µL medium (MOI, 0.3). The final concentration 
of DMSO in the assay was 1%. The growth medium was removed from the wells and 100 µL of 
compound and virus mixture was added to the cells for each compound concentration. At 16 hpi the 
medium was removed, and cells were fixed with 3 % paraformaldehyde (PFA) for 1 h and washed 
with phosphate-buffered saline (PBS). 300 µL PBS was added to each well and the plate was analyzed 
in the Trophos plate runner HD (Trophos, Roche Group) to count the number of virus infected cells 
per well, by identifying all individual cells expressing the far-red fluorescent protein Katushka (Islam 
et al., 2018). The toxicity of compounds was analysed using CTG assay.  
The half-maximal cytotoxic concentration (CC50) and the half-maximal effective concentration 
(EC50) for each compound were calculated after non-linear regression analysis with a variable slope 
using GraphPad Prism software version 7.0a (GraphPad Software La Jolla, CA, USA) or using Hill 
curve fit with SigmaStat 4.0 software (SPSS Inc., Chicago, IL, USA). The relative effectiveness of 
drugs were quantified as the selectivity indexes (SI = CC50/EC50). 
3. Results 
















There is limited information available on approved, investigational and experimental BSAs. To 
identify all potential BSAs, we reviewed all approved, investigational and experimental safe-in-human 
antiviral agents in Drug Bank, Clinical trials website  and PubMed, respectively. First, we searched for 
drugs, which have been approved for treatment of viral diseases in human. By excluding vaccines and 
discontinued drugs, we identified 86 active antiviral substances. These compounds target 30 viral, 6 
human and 3 unknown factors and inhibit 17 viruses (Table S2). The approved antivirals include 5 
neutralizing antibodies, 3 interferons, 1 antisense oligonucleotide, and 76 small molecules. Only 9 of 
the 76 molecules target viruses or host factors associated with ≥3 viral diseases. Figure 1 shows BSAs 
and other approved antiviral drugs linked to viral and host targets through viruses they inhibit.  
Next, we reviewed all investigational antivirals and their safety profiles. By excluding vaccines 
from the search parameters, we found 116 active compounds. These compounds target 42 viral, 29 
human and 7 unknown factors and inhibit 19 viruses (Table S3). The drug candidates include 2 
neutralizing antibodies, 6 antisense oligonucleotides, 5 interferons, 1 enzyme and 100 small molecules. 
Only 4 of the 100 small molecules target ≥3 viral diseases. Figure 2 shows these and other 
investigational antiviral agents linked to cellular and host factors through targeted viruses. 
Next, we searched for drugs, which have been approved for treatment of non-viral diseases, but for 
which antiviral activity has been reported. We found 156 active compounds, which are all small-
molecules. These compounds target 32 viral, 87 human and 3 unknown factors, and inhibit 53 human 
viruses (Table S4). Thirty-nine of the 155 antiviral agents target ≥3 viral diseases. Figure 3 shows 
these and other experimental antiviral agents connected to their host and viral targets through viruses 
they inhibit. 
Altogether, we identified 339 antiviral agents with available safety information in humans. These 
agents target 109 host, 76 viral and 13 unknown factors and inhibit 58 different viruses, belonging to 
20 viral families. Fifty-nine agents have BSA activity (Table S5). These 59 agents target 55 of the 58 
















that several drugs (such as, acyclovir, famciclovir and valacyclovir; imatinib and disatinib; minocyclin 
and doxycycline; ritonavir and lopinavir; hydroxychloroquine and chloroquine; esomeprazole and 
omeprazole) have similar scaffolds (Fig. S2). These drugs target a limited number of host and viral 
factors (Fig. S3). In particular, statins (fluvastatin, lovastatin and simvastatin) target human HMG-
CoA; dalbavancin, oritavancin, teicoplanin and telavancin target human CYP3A4; acyclovir, 
valacyclovir, famciclovir, azacitidine, brincidofovir, cidofovir, foscarnet, trifluridine, and vidarabine 
inhibit viral DNA polymerases; BCX4430, favipiravir and ribavirin inhibit viral RNA polymerases; 
and lamivudine and tenofovir disoproxil inhibit viral reverse transcriptases. 
3.2.  Novel antiviral activities of azacitidine, cyclosporine, minocycline, oritavancin, ritonavir, 
dalbavancin and ezetimibe 
We hypothesized that approved, investigational and experimental antiviral agents, which target ≥3 
viral diseases, could inhibit other viral infections. As a proof of concept, we tested 55 of the 59 
identified BSAs against FLUAV, EV1, CHIKV, RRV and HSV-1 infections in RPE cells (alisporivir, 
CYT107, sunitinib and thymalfasin were excluded; Table S6). We also tested 52 of the 59 BSAs 
against ZIKV infection in RPE cells (alisporivir, CYT107, sunitinib, thymalfasin, dalbavancin, 
pentosan polysulfate and rapamycin were excluded). We evaluated viability and death of virus/mock-
infected cells using CTG and CTxG assays, respectively. The CTG assay quantifies ATP, an indicator 
of metabolically active living cells, whereas CTxG assay uses fluorescent cyanine dye that stains the 
DNA of dead cells. After initial screening we found several hits, which kept infected cells alive or 
rescued infected cells from virus-mediated death. These hits are gemcitabine, gefitinib and vibarabine 
(FLUAV); gemcitabine, pirlindole dibucaine, fluoxetine and dalbavancin (EV1); gemcitabine, 
imatinib, ivermectin, lopinavir, lovastatin, ezetimibe, fluoxetine, BCX4430, chloroquine and 
hydroxychloroquine (ZIKV); chloroquine and mycophenolic acid (CHIKV); chloroquine, 
mycophenolic acid, dibucaine and itraconazole (RRV); as well as 5-azacitidine, gemcitabine, 
















We repeated the CTG and CTxG assays with selected compounds and titrated FLUAV, EV1, ZIKV 
and HSV-1 produced in drug-treated and non-treated cells. The presence of CHIKV and RRV viruses 
in the media collected from non- or drug-treated RPE cells was evaluated by infecting fresh RPE 
cells and measuring reporter protein expression from viral promoter (nanoluciferase activity). These 
experiments confirmed antiviral activity of gemcitabine against FLUAV (Fig. S4); gemcitabine, 
pirlindole, dibucaine, fluoxetine, and dalbavancin against EV1 (Fig. S5); gemcitabine, lopinavir, 
ezetimibe, BCX4430, chloroquine, and hydroxychloroquine against ZIKV (Fig. S6); chloroquine and 
mycophenolic acid against CHIKV (Fig. S7); mycophenolic acid against RRV (Fig. S8); and 
gemcitabine against HSV-1 (Fig. S9). Importantly, dalbavancin and ezetimibe demonstrated novel 
antiviral activities against EV1 and ZIKV, respectively. In particular, they rescued infected RPE cells 
from virus-mediated cell death, and lowered production of infectious virus particles without detectable 
cytotoxicity (Table 1).  
We also examined toxicity and antiviral activity of 55 of the 59 BSA agents (excluding alisporivir, 
CYT107, sunitinib and thymalfasin) against HIV-1 infection in TZM-bl cells. Our primary screen 
identified ezetimibe, minocycline and rapamycin as nti-HIV-1 agents. Validation experiment 
confirmed all three hits (Fig. S10, Table 1). Interestingly, ezetimibe is a novel inhibitor, whereas 
minocycline and rapamycin are known anti-HIV-1 agents (Heredia et al., 2015; Singh et al., 2014).  
In addition, we examined antiviral activity and toxicity of 53 of the 59 BSA agents (alisporivir, 
CYT107, sunitinib, thymalfasin, dalbavancin, pentosan polysulfate and rapamycin were excluded) 
against RVFV expressing the far-red fluorescent proein Katushka in A549 cells. Our screen identified 
azacitidine, bortezamibe, cyclosporine, doxycycline, ezetimibe, fluoxetine, gefitinibe, minocycline, 
oritavancin, ritonavir and topotecan. Azacitidine, cyclosporine, minocycline, oritavancin, ritonavirand 
and bortezamib remained after excluding compounds with SI<2 (Fig. S11; Table 1). Interestingly, 
azacitidine, cyclosporine, minocycline, oritavancin and ritonavirand are novel, whereas bortezamib is a 
















Thus, we tested several known BSA agents against (-)ssRNA, (+)ssRNA, ssRNA-RT and dsDNA 
viruses and identified novel activities for dalbavancin against EV1, ezetimibe against ZIKV and HIV-
1, as well as azacitidine, cyclosporine, minocycline, oritavancin and ritonavir against RVFV. Figure 4 
shows known, validated and novel interactions betwen BSAs and viruses. 
4. Discussion 
Several approved and investigational agents, as well as safe in man chemical probes, were 
discovered for potential treatment of various viral diseases (Bekerman and Einav, 2015; De Clercq, 
2015; De Clercq and Li, 2016). Re-purposing such therapeutics from one viral disease to another could 
save resources and time needed for development of novel drugs. In this study, we tested 55 approved, 
investigational and experimental BSA agents against FLUAV, RVFV, EV1, ZIKV, CHIKV, RRV, 
HIV-1 and HSV-1 in vitro. We identified novel antiviral activities for dalbvancin (against EV1), 
ezetimibe (against HIV-1 and ZIKV), azacitidine, cyclosporine, minocycline, oritavancin and ritonavir 
(against RVFV) (Fig. 4).  
Dalbavancin is a lipoglycopeptide antibiotic, which is approved by the FDA for the treatment of 
acute bacterial skin infections caused by Staphylococcus aureus and Streptococcus pyogenes. 
Dalbavancin also inhibits MERS-CoV and SARS-CoV infections. It binds cathepsin L in the late 
endosomes/lysosomes and blocks the entry of EBOV (Zhou et al., 2016). Our study demonstrates that 
it also inhibits replication of EV1, which also entrs the cells via an endocytic route (Krieger et al., 
2013).  
Ezetimibe is an FDA-approved medication that lowers plasma cholesterol by decreasing its 
absorption in the small intestine. Ezetimibe also inhibits HBV and HDV infections by impairing viral 
entry mediated by preS1-specific receptor hNTCP (Blanchet et al., 2014; Lempp and Urban, 2014; 
Monrroy-Bravo et al., 2016). Our study shows that ezetimibe also inhibited HIV-1 and ZIKV 
infections. However, the entry of these viruses into the cell is mediated by other receptors (Hamel et 
















is associated with depletion of cholesterol which is required for entry of these viruses into the host 
cells (Sainz et al., 2012). Importantly, this drug was successfully tested in combination with 
antiretroviral therapeutics to lower cholesterol levels in serum of HIV-infected patients (Saeedi et al., 
2015; Wohl et al., 2008). The question remains whether ezetimibe alone reduces HIV titers in these 
patients.  
Azacitidine is a chemical analogue of cytidine, which s used in the treatment of myelodysplastic 
syndrome. It also inhibits FLUAV, AdV, HIV-1 and HIV-2 replication by blocking viral RNA or DNA 
synthesis (Beach et al., 2014; Rawson et al., 2016). Cyclosporine is an immunosuppressive agent used 
for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, nephrotic syndrome and 
keratoconjunctivitis sicca. In addition, cyclosporine is used to prevent graft rejection in organ 
transplant recipients. Cyclosporine also inhibits HCV, FLUAV, WNV and ZIKV replication through 
blocking interaction of cellular cyclophilins with viral proteins and attenuating viral RNA synthesis 
(Barrows et al., 2016; Firpi et al., 2006; Qing et al., 2009). Minocycline is a broad-spectrum antibioic 
and antiviral agent, which possesses activity against DENV, HIV-1 and WNV (Leela et al., 2016; 
Quick et al., 2017; Singh et al., 2014). Oritavancin is a semisynthetic glycopeptide antibiotic used for 
the treatment of Gram-positive bacterial skin infections. It also inhibits EBOV, MERS-CoV, and 
SARS-CoV infections (Zhou et al., 2016). Ritonavir is an antiretroviral medication. It has also antiviral 
activity against MERS-CoV (Chan et al., 2015). We showed that azacitidine, cyclosporine, 
minocycline, oritavancin and ritonavir are active against RVFV. 
We also confirmed previously reported activities of chloroquine against CHIKV and ZIKV, 
mycophenolic acid against CHIKV and RRV, fluoxetine, pirlindole and dibucaine against EV1, 
BCX4430, lopinavir and hydroxichloroquine against ZIKV, as well as gemcitabine against EV1, 
FLUAV, ZIKV and HSV-1 (Cao et al., 2017; Delogu and de Lamballerie, 2011; Delvecchio et al., 
2016; Denisova et al., 2012; Julander et al., 2017; Kang et al., 2015; Khan et al., 2011; Kuivanen et al., 
















The number of compounds with novel and confirmed antiviral properties may have been higher if 
we had used other cell lines, other viruses and viral strains, concentration ranges and purity of 
compounds, as well as endpoint measurements. Also testing other compounds, which target <3 viral 
diseases, could reveal novel antiviral properties of these compounds and increase the number of 
potential BSAs. For conducting this properly, a harmonized antiviral bioactivity data annotation, 
standardization, curation, and intra-resource integration is needed.  
Excellent antiviral profiles from cell-line-based ass ys might not be reflected in vivo because 
systemic mechanisms may compensate the blocked target effect. Therefore, the identification of BSA 
targets that are essential for viral replication but redundant for the cell is critical for reducing putative 
toxicities associated with blocking cellular pathways. The level of toxicity that can be tolerated 
depends on the viral threat and the required time of treatment. Thus, follow-up mechanistic and i  vivo 
studies are needed to validate our in vitro results. 
In conclusion, repositioning of safe-in-man agents from one viral disease to another could play a 
pivotal role in development of broadly acting antivirals. Our study demonstrated the potential value of 
such approach with some examples, such as dalbavancin, ezetimibe, azacitidine, cyclosporine, 
minocycline, oritavancin and ritonavir, confirming a principle that “rich becomes richer“.  
Effective BSA treatment may shortly become available, pending the results of further pre-clinical 
studies and clinical trials. The most effective and tolerable compounds will expand the available 
therapeutics for the treatment of viral diseases. Some of these compounds could be used as first-
line therapeutics to combat emerging and re-emerging viral threats. In the future, they will have global 
impact, improving preparedness and the protection of the general population from viral epidemics and 
pandemics. 
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Table 1. Half-maximal cytotoxic concentration (CC50), the half-maximal effective concentration (EC50) and minial 
selectivity indexes (SI) for selected broad-spectrum antivirals. CTxG - CellTox Green Express cytotoxicity assay, CTG - 
CellTiter-Glo viability assay, other – plaque assay or reporter gene expression assay, n.a. – not available. 
 
Antiviral agent Virus Cells CC50 (µM) EC50 (µM) SI 
CTxG CTG CTxG CTG other  
Azacitidine RVFV A549 n.a. >100 n.a. n.a. 11,42 >9 
BCX4430 ZIKV RPE >30 >30 2,96 18,47 13,12 >2 
Bortezamib RVFV A549 n.a. >100 n.a. n.a. <0,39 >256 
Chloroquine ZIKV RPE >30 >30 n.a. 7,25 n.a. >4 
Chloroquine CHIKV RPE >30 >30 9,15 12,81 16,84 >2 
Cyclosporine RVFV A549 n.a. 13,45 n.a. n.a. 5,78 >2 
Dalbavancin EV1 RPE >30 >30 18,73 3,23 9,72 >2 
Dibucaine EV1 RPE >30 >30 2,05 n.a. 0,96 >15 
Ezetimibe ZIKV RPE >30 >30 0,09 n.a. n.a. >333 
Ezetimibe HIV-1 TZM-bl >30 n.a. n.a. n.a. 13,19 >2 
Fluoxatine EV1 RPE 7,33 4,02 0,72 0,34 2,16 2 
Gemcitabine FLUAV RPE >30 >30 1,02 0,25 0,89 >29 
Gemcitabine EV1 RPE >30 >30 0,08 n.a. 6,96 >4 
Gemcitabine ZIKV RPE 21,78 >30 0,07 0,92 n.a. 23 
Gemcitabine HSV-1 RPE >30 >30 n.a. 0,05 n.a. >500 
Hydroxychloroquine ZIKV RPE >30 >30 0,06 22,99 n.a. >1 
Lopinavir ZIKV RPE >30 >30 n.a. 12,01 24,08 >1 
Minocycline RVFV A549 n.a. >100 n.a. n.a. 9,52 >11 
Minocycline HIV-1 TZM-bl >30 n.a. n.a. n.a. 6,84 >6 
Mycophenolic acid CHIKV RPE >30 >30 0,08 n.a. 0,09 >333 
Mycophenolic acid RRV RPE >30 >30 n.a. 3,19 0,86 >9 
Oritavancin RVFV A549 n.a. 75,81 n.a. n.a. 4,49 >17 
Pirlindole EV1 RPE >30 28,52 2,71 n.a. 8,92 11 
Rapamycin HIV-1 TZM-bl >30 n.a. n.a. n.a. 18,86 >1 















Fig. 1. Eye diagram showing approved drugs for the treatmen  of viral diseases in human (left), their viral and host targets 















Fig. 2. Eye diagram showing antiviral agents in clinical trials (left), their viral and host targets (right), as well as viruses 















Fig. 3. Eye diagram showing approved drugs for the treatmen  of non-viral diseases (left), which also possess antiviral 
activity, their viral and host targets (right), as well as viruses they inhibit (middle). Broad-spectrum antiviral agents are 
















Fig. 4. The interaction network between 55 viruses and 59 BSAs, which are safe in man. Drug-like shapes represnt 
antiviral agents. Blue spheres represent viruses. The diameter of spheres corresponds to the number of interactions between 















• 339 approved, investigational and experimental safe-in-human antivirals were identified 
• 59 compounds, which target ≥3 viral diseases, were selected 
• 55 of the 59 compounds were tested against 8 RNA and DNA viruses 
• 7 compounds were found to possess novel antiviral activities 
